Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 40.85 HKD | -4.11% | -7.79% | -29.45% | |
| Nov. 22 | RemeGen Gets Full Approval for Telitacicept | MT |
| Nov. 22 | RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA | CI |
| Sales 2023 * | 1.19B 167M 1.3B | Sales 2024 * | 1.93B 269M 2.1B | Capitalization | 31.62B 4.42B 34.51B |
|---|---|---|---|---|---|
| Net income 2023 * | -1.22B -170M -1.33B | Net income 2024 * | -835M -117M -911M | EV / Sales 2023 * | 26,0x |
| Net cash position 2023 * | 663M 92.57M 723M | Net Debt 2024 * | 402M 56.12M 438M | EV / Sales 2024 * | 16,6x |
| P/E ratio 2023 * | -17,5x | P/E ratio 2024 * | -25,9x | Employees | 3,332 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 51.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.17% | ||
| 1 week | -6.88% | ||
| Current month | -8.64% | ||
| 1 month | -12.23% | ||
| 3 months | +24.25% | ||
| 6 months | +32.64% | ||
| Current year | -28.76% |
1 week
39.25
46.65
1 month
39.2549.00
Current year
29.7074.80
1 year
29.7074.80
3 years
25.05149.80
5 years
25.05149.80
10 years
25.05149.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Min Fang
CEO | Chief Executive Officer | 61 | 2008 |
Ruyi He
CTO | Chief Tech/Sci/R&D Officer | 62 | 2020 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xian Jing Hao
BRD | Director/Board Member | 58 | 2020 |
Jian Min Fang
CEO | Chief Executive Officer | 61 | 2008 |
Ruyi He
CTO | Chief Tech/Sci/R&D Officer | 62 | 2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.38% | 3 M€ | -29.97% | - | |
| 1.27% | 4 M€ | -27.92% | ||
| 0.95% | 72 M€ | -23.27% | ||
| 0.64% | 5 M€ | -19.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 40.85 | -4.11% | 1 025 498 |
| 23-12-05 | 42.6 | +2.28% | 1,309,500 |
| 23-12-04 | 41.65 | -7.75% | 3,439,500 |
| 23-12-01 | 45.15 | 0.00% | 1,547,000 |
| 23-11-30 | 45.15 | +1.92% | 1,399,870 |
Delayed Quote Hong Kong Stock Exchange, December 06, 2023 at 02:00 am EST
More quotes
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-03-21
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
38.92CNY
Average target price
52.41CNY
Spread / Average Target
+34.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.76% | 4 426 M $ | |
| +13.78% | 87 300 M $ | |
| -7.78% | 31 003 M $ | |
| +23.14% | 27 349 M $ | |
| -34.27% | 23 472 M $ | |
| -25.30% | 20 775 M $ | |
| -16.27% | 19 181 M $ | |
| -0.75% | 11 647 M $ | |
| +24.64% | 11 318 M $ | |
| -31.98% | 8 245 M $ |
